BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dinutuximab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dinutuximab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02573896-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dinutuximab: Phase 1 readout est. (NCT02573896)
DESCRIPTION:Dinutuximab\, phase 1\, Neuroblastoma.\nStudy: Immunotherapy of
  Relapsed Refractory Neuroblastoma With Expanded NK Cells\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dinutuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT02573896
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04211675-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dinutuximab: Phase 1/2 readout est. (NCT04211675)
DESCRIPTION:Dinutuximab\, phase 1/2\, Neuroblastoma.\nStudy: NK Cells Infus
 ions With Irinotecan\, Temozolomide\, and Dinutuximab\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dinutuximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04211675
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05421897-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Dinutuximab: Phase 2 readout est. (NCT05421897)
DESCRIPTION:Dinutuximab\, phase 2\, Neuroblastoma.\nStudy: Rapid Administra
 tion Pilot for Infusing Dinutuximab\nEstimated primary completion: Novembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dinutuximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05421
 897
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06450041-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dinutuximab: Phase 2 readout est. (NCT06450041)
DESCRIPTION:Dinutuximab\, phase 2\, Neuroblastoma.\nStudy: NANT 2021-01 Pha
 se II STING (Sequential Temozolomide\, Irinotecan\, NK Cells and GD2 mAb) 
 Trial\nEstimated primary completion: December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dinutuximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06450041
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07437963-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Dinutuximab: Phase 1/2 readout est. (NCT07437963)
DESCRIPTION:Dinutuximab\, phase 1/2\, Neuroblastoma.\nStudy: Testing the Ad
 dition of Iberdomide to Therapy in People With Neuroblastoma That Has Come
  Back\, Not Responded to Treatment\, or Gotten Worse\nEstimated primary co
 mpletion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dinutuximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07437963
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172296-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dinutuximab: Phase 3 readout est. (NCT06172296)
DESCRIPTION:Dinutuximab\, phase 3\, Neuroblastoma.\nStudy: Dinutuximab With
  Chemotherapy\, Surgery and Stem Cell Transplantation for the Treatment of
  Children With Newly Diagnosed High Risk Neuroblastoma\nEstimated primary 
 completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dinutuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06172296
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03126916-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Dinutuximab: Phase 3 readout est. (NCT03126916)
DESCRIPTION:Dinutuximab\, phase 3\, Neuroblastoma.\nStudy: Testing the Addi
 tion of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-R
 isk Neuroblastoma (NBL)\nEstimated primary completion: 30 September 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dinutuximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03126916
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261241-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Dinutuximab: Phase 2 readout est. (NCT07261241)
DESCRIPTION:Dinutuximab\, phase 2\, Neuroblastoma.\nStudy: NANT 2021-02: Ra
 ndomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab\nEstima
 ted primary completion: 31 December 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dinutuximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07261241
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932808-10833@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20311126
DTEND;VALUE=DATE:20311127
SUMMARY:Dinutuximab: Phase 2 readout est. (NCT07932808)
DESCRIPTION:Dinutuximab\, phase 2\, Neuroblastoma.\nStudy: Naxitamab Enable
 d Transplant-Free Study in High-Risk Neuroblastoma\nEstimated primary comp
 letion: 26 November 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dinutuximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07932808
URL:https://assetmemo.bio/drug/dinutuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
